Aureobasidium.org

patent 2023

Biological healing accelerator-EU (European Patent No. 2098240)

Iwai A., Uchiyama H. · European Patent Office
Research Archive
TL;DR — Key Findings
  • EU patent protects AP β-glucan as biological healing accelerator.
  • European patent demonstrates international recognition of AP-glucan healing properties.
  • Multi-country patent portfolio supports global commercialization of AP-glucan therapeutics.

Abstract

Biological healing accelerator-EU (European Patent No. 2098240)

Patent Details

Country of RegistrationEurope

Patent No.No. 2098240Registration DateSeptember 11, 2013Remarks※ Reduction of side effects of anti-cancer drugs

Currently, Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) has been approved in Japan, Europe (UK, France, Germany), China, Hong Kong, Taiwan, and Thailand to reduce the side effects of anticancer drugs and to promote healing of erythema caused by burn wounds.

Summary

Summary

Patent Overview

European Patent No. 2098240 covers Aureobasidium pullulans-derived β-glucan as a biological healing accelerator for the European market. This patent protects the use of N-163 strain β-glucan formulations to enhance tissue repair and immune recovery processes.

Significance

This EU patent extends intellectual property protection for Aureobasidium pullulans β-glucan's biological healing acceleration applications across European member states, part of an international patent family including JP, US, CN, TW, and HK equivalents.

Citation

Iwai A., Uchiyama H.. Biological healing accelerator-EU (European Patent No. 2098240). European Patent Office. 2023.

Study Details
Study Type
patent
Published
2023
Journal
European Patent Office
Authors
Iwai A., Uchiyama H.
Important Notice

For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.